Nu Skin Enterprises ((NUS)) has held its Q1 earnings call. Read on for the main highlights of the call.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Nu Skin Enterprises’ latest earnings call struck a cautiously optimistic tone, as management highlighted early wins from its Prysm iO wellness platform, steady subscription growth, and solid demand for key nutrition products, even while acknowledging pressure on margins and profitability. Executives stressed disciplined execution and a stronger balance sheet, signaling confidence in long-term growth despite near-term cost headwinds.
Revenue in Line with Guidance
Nu Skin reported first-quarter revenue of $320.6 million, landing within its guided range and benefiting from a 1% tailwind from foreign exchange. Management chose to maintain full-year guidance, indicating that a clearer picture of the trajectory will emerge after the second quarter as new initiatives scale and macro conditions evolve.
Adjusted EPS Tracks Expectations
Adjusted earnings per share came in at $0.14, aligned with internal expectations after excluding charges tied to winding down the BeautyBio business and other items, while GAAP EPS was a modest $0.04. The spread between adjusted and GAAP results underscored the cost of portfolio cleanup and strategic investment, which is temporarily dampening reported profitability.
Prysm iO Adoption and Data Scale Build Momentum
The company underscored strong early traction for its Prysm iO device, with nearly 2 million scans generated from more than 30,000 devices in the field, on top of 20 million historical biophotonics scans. Subscription volume increased 5% year over year, and subscribers as a share of total customers climbed 14%, reinforcing management’s pivot to recurring, data-driven wellness solutions.
Nutrition Ecosystem and LifePak Drive Growth
Products certified to improve Prysm iO scores are outperforming the broader portfolio, validating Nu Skin’s measurement-based wellness strategy. Its flagship LifePak brand delivered more than 10% year-over-year growth, suggesting that data-backed claims and integrated nutrition offerings are resonating with consumers seeking tangible health outcomes.
Regional Momentum in Latin America and China
Latin America continued to post sustained growth, while Mainland China showed further signs of stabilization and improvement, helped by strong leader engagement around the Tru Face anti-aging rollout. Management also reported steady progress in India, where the business remains in a pre-market phase ahead of a planned formal launch later in the year.
Stronger Balance Sheet and Capital Returns
Nu Skin completed a refinancing that extends its credit maturities out to 2031 and improves its borrowing costs, giving the company additional financial flexibility. The firm returned roughly $8 million to shareholders through $3 million in dividends and $5 million in share repurchases, leaving $137.3 million of repurchase authorization still available.
Gross Margin Stable with Core Improvement
Core Nu Skin gross margin improved to 76.9%, 20 basis points higher than a year ago, reflecting favorable mix and ongoing efficiency efforts in the core business. On a consolidated basis, adjusted gross margin held essentially flat at 67.9% versus 67.8% last year, showing that overall pricing and product economics remain intact despite macro cost pressures.
Operating Margin Under Pressure
Adjusted operating margin declined to 3.6% from 6.4% in the prior-year quarter, a 280-basis-point drop tied to elevated investment and structural costs. Management framed this as a deliberate trade-off, emphasizing that spending is being channeled into strategic priorities such as technology, Prysm iO deployment, and new market development.
Higher Selling Expenses to Support Productivity
Selling expense rose to 34.3% of revenue from 32.5% a year earlier, with core selling expense climbing to about 40.5% from 38.7%, an increase of roughly 180 basis points. The higher spending reflects enhanced compensation plans aimed at rewarding sales leader productivity, which the company believes will support future growth even as it weighs on near-term margins.
G&A Rate Rises Despite Cost Cuts
Adjusted general and administrative expense declined by $9 million year over year in absolute dollars, signaling tangible cost discipline. However, G&A as a percentage of revenue increased to 29.9% from 28.9%, as Nu Skin continues to invest in technology infrastructure and emerging-market expansion that should underpin scalable growth over time.
Prysm iO Transition Creates Near-Term Costs
Management acknowledged that shifting sales leaders from demo-focused pitches to a consultative wellness model around Prysm iO brings short-term switching costs. Training, new CRM tools, and behavior changes are temporarily dampening productivity and margin, but the company argues these investments are crucial to building a differentiated, data-centric customer experience.
Macro and Geopolitical Headwinds Persist
The call also highlighted ongoing external pressures, including tariffs, supply chain challenges, and rising fuel costs, which are amplifying inflation across consumer goods and in some cases pushing prices up by as much as 16%–30%. These forces risk suppressing demand and slowing margin recovery, especially in more sensitive or price-conscious markets.
Segment Pressures and Limited Near-Term India Contribution
Certain reporting segments remain under strain from broader industry and macro dynamics, limiting their contribution to overall growth in the near term. India, while a strategic focus, is being operated as a learning-focused pre-market entry, with management signaling that revenue from this market will likely remain limited through 2026.
Modest GAAP EPS Reflects Investment Phase
GAAP earnings per share were a modest $0.04 for the quarter, highlighting the drag from restructuring charges and expansion-related investments. The muted bottom line underscores that Nu Skin is still in an investment-heavy phase, prioritizing platform build-out and portfolio optimization over short-term profit maximization.
Forward Guidance and Outlook
Nu Skin reiterated its full-year guidance and set second-quarter revenue expectations between $330 million and $360 million, with EPS forecast in the $0.15 to $0.25 range assuming relatively neutral currency effects. Management expects sequential improvement from the first quarter, plans to continue investing in Prysm iO and emerging markets, and promised greater visibility on the 2024 trajectory after Q2.
Nu Skin’s earnings call painted a picture of a company in transition, balancing tangible progress in digital wellness, nutrition, and regional expansions against compressed margins and macro uncertainty. For investors, the story hinges on whether early traction in Prysm iO, subscription growth, and a fortified balance sheet can eventually translate into sustained revenue gains and a recovery in profitability.